BMS Selects Quintiles as Third Preferred Labs Provider; Icon May be Dropped
Bristol-Myers Squibb (B-MS) has signed up Quintiles as a central labs supplier, prompting more questions about Icon’s status as a preferred provider of laboratory services.
Archives for April 14, 2013
Rise of Russia as EMA Reports Global Stretch of Clinical Trials
An EMA report says increased Russian participation in European submitted clinical trials is part of a trend away from traditional regions, yet fluctuating legislation may affect numbers.
Novaliq Secures Funds to Develop Ocular Delivery Tech
Novaliq has raised funds to further development of its bioavailability boosting delivery technology and take its candidate dry eye drug into Phase I trials.
BMS Plant Expansion to Push Biologics Development and Manufacturing
Bristol Myers-Squibb says its $250m (€191m) expansion of its US biologics facility will centralize its processes and become a springboard to launch new products.
Update
Thermo Fisher Acquires Life Tech for $13.6B
Thermo Fisher Scientific has agreed to purchase genetic testing equipment maker Life Technologies for $13.6B in one of the biggest acquisitions of the year.
ICH Draft Guidance Aims to Help Stamp Out Drug Impurities
The US FDA has opened for public comment a new ICH draft guideline that aims to help manufacturers identify and control mutagenic impurities during the development of new drugs.